TrialBMC cancer2014

TIMP-1 and responsiveness to gemcitabine in advanced breast cancer; results from a randomized phase III trial from the Danish breast cancer cooperative group.

Charlotte Levin Tykjær Jørgensen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.